Tag Archive | "AstraZeneca"

AstraZeneca signs pharma deal with Qiagen

Tags: , , , ,


AstraZeneca has entered into a pharma deal with  QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA. Read the full story

AstraZeneca signs a pharma alliance with Roche

Tags: , , ,


AstraZeneca has entered into pharma alliance with Roche to develop a plasma-based companion diagnostic test. Read the full story

AstraZeneca signs pharma licensing with Synairgen

Tags: , , ,


AstraZeneca announced a global licence agreement with Synairgen for SNG001. Read the full story

Cancer Genetics signs biotech deal with AstraZeneca

Tags: ,


Cancer Genetics has been selected by AstraZeneca for a biotech deal to provide biomarker-based diagnostic testing for cancer. Read the full story

Top 50 Pharma (top pharmaceutical companies)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,


The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

AstraZeneca

Tags: ,


AstraZeneca is a top pharmaceutical company based in London, United Kingdom Read the full story

Pfizer gives up on AstraZeneca

Tags: , , ,


Pfizer has given up on its attempt to take over the British pharmaceutical company AstraZeneca.
Read the full story

AstraZeneca rejects Pfizer’s final offer, again

Tags: , , ,


On Friday May 16th, 2014, Pfizer announces its final proposal to combine the two companies. Read the full story

AstraZeneca forms a pharma partnering with University of Exeter

Tags: , ,


The University of Exeter has announced a unique pharma partnering that will pioneer world-leading research to boost the effectiveness and safety of vital new drugs for both patients and the environment. Read the full story

AstraZeneca rejects Pfizer’s takeover offer

Tags: , , , ,


The board of pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer’s sweetened takeover offer just hours after it was levelled, describing it as inadequate. Read the full story